Non Alcoholic Fatty Liver Disease (NAFLD) Market- Pipeline Review, H1 2018Posted by Neel Patel on January 30th, 2018 Latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2018, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape. Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort. Report Highlights AlgoroReports Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 18, 10, 24, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively. Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from AlgoroReports proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Get Sample Report @ https://www.algororeports.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-review-h1-2018 Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal). Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. About Us: AlgoroReports is a part of Algororesearch consultant Pvt. Ltd. AlgoroReports is one of the largest collections of market research reports from numerous publishers with the team of industries specialist that meet with best client requirements. Market Research is based on a research project that may also be an expansion on past work in the field. Research projects can be used to develop further knowledge on a topic, geography, culture, linguistics, and community to provide exact idea about existing market. Contact Us Like it? Share it!More by this author |